Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bitter hops extract is an investigational botanical extract derived from a New Zealand commercial variety of hop flowers (*Humulus lupulus* L.) using a food-grade supercritical carbon dioxide extraction process. It is marketed as a gut-targeted dietary supplement under the brand name Amarasate (and formulated in the commercial product Calocurb) for appetite suppression and weight management. The extract contains concentrated bitter hop acids, including alpha-acids (such as humulone) and beta-acids (such as lupulone), which act as ligands for human bitter taste receptors (TAS2Rs) located on enteroendocrine cells in the gastrointestinal tract. Activation of these receptors triggers the 'bitter brake' satiety mechanism, stimulating the release of appetite-regulating gut hormones, including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY), which signal fullness to the brain and reduce energy intake.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bitter hops extract.